14 02, 2019 Lorenza Rimassa et al., Phase 2 study of tivantinib and cetuximab in KRAS wild-type metastatic colorectal cancer patients with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition Marco Amadio 2020-01-22T12:34:31+00:00 Leggi di più